Literature DB >> 26123464

Refractory hypocalcaemia complicating metastatic prostatic carcinoma.

Christopher Rizzo1, Sandro Vella1, Mario J Cachia1.   

Abstract

A 72-year-old man with a background of ischaemic heart disease was referred to the accident and emergency department with a 1-week history of worsening dyspnoea and lethargy. A chest X-ray revealed a right-sided lobar pneumonia and a prolonged corrected QT interval was noted on his ECG at presentation. Laboratory investigations confirmed severe hypocalcaemia, significant vitamin D deficiency and relative hypoparathyroidism. A markedly elevated prostate-specific antigen was also identified. Bone scintigraphy demonstrated widespread osteoblastic bone metastases. Severe hypocalcaemia persisted despite treatment and he succumbed after 60 days of hospitalisation. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26123464      PMCID: PMC4488614          DOI: 10.1136/bcr-2015-210003

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  17 in total

1.  Hyperparathyroidism due to the so-called bone hunger syndrome in prostate cancer patients.

Authors:  Alfredo Berruti; Luigi Dogliotti; Marcello Tucci; Roberto Mario Scarpa; Alberto Angeli
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

2.  Metabolic studies in a case of hypocalcemia and osteoblastic metastases.

Authors:  C L Tommaso; J R Tucci
Journal:  Arch Intern Med       Date:  1979-02

3.  Renal tubular reabsorption of phosphate is positively related to the extent of bone metastatic load in patients with prostate cancer.

Authors:  N Buchs; J P Bonjour; R Rizzoli
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

4.  Hypocalcemia and parathyroid function in metastatic prostate cancer.

Authors:  Prabhat K Tandon; Ali A Rizvi
Journal:  Endocr Pract       Date:  2005 Jul-Aug       Impact factor: 3.443

5.  Hypocalcemia associated with metastatic bone disease. A retrospective study.

Authors:  P Raskin; C J McClain; T A Medsger
Journal:  Arch Intern Med       Date:  1973-10

6.  Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases.

Authors:  A Berruti; L Dogliotti; G Gorzegno; M Torta; M Tampellini; M Tucci; S Cerutti; M M Frezet; M Stivanello; G Sacchetto; A Angeli
Journal:  Clin Chem       Date:  1999-08       Impact factor: 8.327

Review 7.  Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease.

Authors:  Colin R Dunstan; Dieter Felsenberg; Markus J Seibel
Journal:  Nat Clin Pract Oncol       Date:  2007-01

8.  Biochemical picture accompanying sclerotic bone metastases of prostatic origin.

Authors:  S Minisola; G Perugia; A Scarda; L Scarnecchia; D Tuzzolo; W Rossi; G Mazzuoli
Journal:  Br J Urol       Date:  1987-11

9.  Hypocalcemia in patients with prostate cancer.

Authors:  S C Kukreja; A Shanmugam; T E Lad
Journal:  Calcif Tissue Int       Date:  1988-12       Impact factor: 4.333

10.  Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency.

Authors:  R K Rude; S B Oldham; F R Singer
Journal:  Clin Endocrinol (Oxf)       Date:  1976-05       Impact factor: 3.478

View more
  3 in total

1.  Hungry bone syndrome secondary to prostate cancer successfully treated with radium therapy.

Authors:  Vishnu Vardhan Garla; Sohail Salim; Karthik Reddy Kovvuru; Angela Subauste
Journal:  BMJ Case Rep       Date:  2018-07-06

Review 2.  Severe and refractory hypocalcaemia secondary to osteoblastic bone metastases in bladder signet ring carcinoma: A case report and literature review.

Authors:  Wanling Zeng; Du Soon Swee
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

3.  Lessons learned from the management of Hungry Bone Syndrome following the removal of an Atypical Parathyroid Adenoma.

Authors:  Dimos Florakis; Stavros Karakozis; Sophia Tseleni-Balafouta; Polyzois Makras
Journal:  J Musculoskelet Neuronal Interact       Date:  2019-09-01       Impact factor: 2.041

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.